MedPath

Dipole Density Right Atrial Mapping and Assessment of Therapy In Cavotricuspid Isthmus Flutter

Not Applicable
Completed
Conditions
Atrial Flutter
Interventions
Device: Acutus Medical System Mapping
Registration Number
NCT01872052
Lead Sponsor
Acutus Medical
Brief Summary

Study to determine the feasibility of the Acutus Medical System in obtaining data to create Dipole Density Maps of electrical activation in the right atrium in patients with typical atrial flutter.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
9
Inclusion Criteria
  • Age 18-75 years
  • One documented occurrence of typical AFL within the past 6 months
  • Be able and willing to sign informed consent
Exclusion Criteria
  • Contraindication to a non-emergent interventional EP procedure
  • Require treatment in or access to left atrium
  • Had a myocardial infarction within the prior two months
  • Had cardiac surgery within the prior three months
  • Intracardiac thrombus
  • Permanent pacemaker/ICD leads in/through right atrium
  • Clinically significant tricuspid valve regurgitation or stenosis
  • Cerebral ischemic event (including TIA) in the prior six months
  • Pregnant
  • Currently enrolled in any other clinical investigation
  • Any other significant uncontrolled or unstable medical condition

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Acutus Medical SystemAcutus Medical System Mapping-
Primary Outcome Measures
NameTimeMethod
The number of patients in which offline construction of pre- and post-treatment activation maps can be completed3 months post-procedure

Proprietary software algorithms will be used generate electrical activation maps based dipole density data acquired by the Acutus Medical Catheter during the procedures. These activation maps will then be applied to a 3D model of the endocardial surface to create a 3D activation map.

The number of patients that experience a device-related adverse events as a measure of safety and tolerability7 days post-procedure
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

AZ Sint-Jan

🇧🇪

Brugge, Belgium

© Copyright 2025. All Rights Reserved by MedPath